<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02876198</url>
  </required_header>
  <id_info>
    <org_study_id>MMT_2015_41</org_study_id>
    <nct_id>NCT02876198</nct_id>
  </id_info>
  <brief_title>Study of the Modification of the Retinal Nerve Fiber Layer in Patients Treated With Intravitreous Injection of Anti-VEGF</brief_title>
  <acronym>IVT-RNFL</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <brief_summary>
    <textblock>
      The intra-vitreous injection (IVT) of anti-VEGF (vascular endothelial growth factor) is
      currently the standard treatment for retinal neovascularization. The VEGF stimulates
      endothelial cells' proliferation and migration. It also increases microvascular permeability.
      If the VEGFs have proven their efficiency in the decrease of choroidal neovascular
      proliferation, their impact of the head of the optic nerve's microvasculature is yet unknown.
      Knowing that this microvasculature provides the retinal nerve fibers with oxygen, located in
      the area of the head of the optic nerve, a vasoconstriction induced by the anti-VEGF may have
      an incidence on the loss of retinal nerve fibers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2016</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change in RNFL's thickness in the nasal quadrant of the optic nerve after intra-vitreous Injection of Anti-VEGF</measure>
    <time_frame>Change from baseline RNFL's thickness at Month 12</time_frame>
    <description>RNFL's thickness (in microns) measured with the Heildelberg glaucoma module of the spectral domain Optical Cohérence Tomographie (OCT Spectralis, Heidelberg engeening).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Retinal Neovascularization</condition>
  <arm_group>
    <arm_group_label>Patients treated with anti-VEGF</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gonioscopy</intervention_name>
    <description>Study of the trabecular structure by gonioscopy</description>
    <arm_group_label>Patients treated with anti-VEGF</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited during a consultation in ophtalmology after prescription of an
        anti-VEGF treatment.

        The study will not change the patient's usual care schedule. Only a different analysis of
        the images obtained by SD -OCT will be performed, and a gonioscopy will be carried out
        systematically the inclusion of patient and 12 months.

        The data for the study will be collected at the inclusion visit and at the final visit of
        the study at 12 months.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years old

          -  Patients treated with anti-VEGF according to the French summary of product
             characteristics (SPC)

          -  Patients who have been informed of the trial and who are not opposed to participate in
             the study

        Exclusion Criteria:

          -  Patients presenting a retinal condition, including the optic nerve

          -  Patients treated with anti-VEGF in both eyes

          -  Pregnant women

          -  Lack of affiliation to social security or universal health coverage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laurence Salomon, MD</last_name>
    <phone>+33 1 48 03 64 31</phone>
    <email>lsalomon@for.paris</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Pole Vision du val d'Ouest</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Flore De Bats, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondation Ophtalmologique A. de Rotchschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Salomon, MD</last_name>
      <phone>+33148036431</phone>
      <email>lsalomon@for.paris</email>
    </contact>
    <investigator>
      <last_name>Martine Mauget-Faÿsse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre médical et chirurgical de la rétine</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benjamin Wolff, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>August 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retinal neovascularization</keyword>
  <keyword>Anti-VEGF</keyword>
  <keyword>Retinal Nerve Fiber Layer (RNFL)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Retinal Neovascularization</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

